-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Starting from the "4+7" pilot in 2018, the current drug centralized procurement has reached the sixth round.
The centralized procurement has attracted the participation of a large number of pharmaceutical companies through the principle of "price-for-quantity"
.
Data show that the purchase volume of selected drugs increased by 265%, which in turn drove the price reduction of unselected drugs, including unselected original research drugs, and some products even fell by 34%, bringing benefits to patients
.
At the press conference on changes in the use of unselected original research drugs held on December 15th, 9 original drugs including atorvastatin oral regular-release dosage form and amlodipine oral regular-release dosage form were introduced, and the results of the collection were compared before and after implementation.
In terms of prices and procurement volume in one year, the procurement volume of unselected original research drugs has been significantly reduced.
The year after the implementation of centralized procurement results has dropped by an average of 46% compared with the year before implementation
.
In terms of prices, the average drop of the unselected original research drugs of the 9 drugs reached 12.
9%
.
Among them, the price of the original research drug of the heavy blood pressure lowering drug-valsartan oral regular-release dosage form has dropped by 20.
8%
.
This product is the third batch of collected varieties.
Five local companies including Changzhou Siyao, China Resources SECCO, Huahai Pharmaceutical, Hunan Qianjin Xiangjiang and Tianda Pharmaceutical won the bid.
The original research manufacturer Novartis was not selected
.
According to data from Meinenet, in 2020, the total sales of valsartan in Chinese public medical institutions and physical pharmacies in cities in China will exceed 5 billion yuan
.
Followed by the oral regular-release dosage form of atorvastatin, which decreased by 20.
7%
.
In the centralized procurement and expansion carried out in 2019, the winning bidders of the lipid-lowering drug atorvastatin calcium were Qilu Pharmaceutical, Xin'an Pharmaceutical, and Lepu, while the original research Pfizer did not win the bid
.
According to data from Menet.
com, the size of the terminal chemical drug market in physical pharmacies in key cities in 2020 will exceed 50 billion yuan, of which atorvastatin calcium tablets top the list with 1.
06 billion yuan
.
It was once again an oral regular-release dosage form of rosuvastatin, with a decrease of 19.
0%
.
This product is a selective HMG-CoA reductase inhibitor, suitable for the treatment of primary hypercholesterolemia or mixed dyslipidemia that cannot be properly controlled after diet control and other non-drug treatments (such as exercise therapy, weight loss) Dyslipidemia
.
The original research manufacturer of rosuvastatin was AstraZeneca.
It is understood that in the "4+7" centralized procurement pilot, the winning bidder was Jingxin Pharmaceutical, while in the expansion of centralized procurement, the winning bidder of rosuvastatin included overseas companies.
Zhengyao, Sandoz, Zhengda Tianqing
.
According to data from Menet.
com, the total sales of rosuvastatin calcium tablets in China's public medical institutions and retail pharmacies in cities in China in 2017 were 5.
839 billion yuan, of which the sales in China's public medical institutions were 5.
019 billion yuan, a year-on-year increase The annual growth rate was 22.
86%
.
In addition, hydromagnesium carbonate chewable tablets, the decline has reached 6.
5%
.
Chewable hydrotalcite is a commonly used gastro-protective medicine, which protects the gastrointestinal tract by directly neutralizing gastric acid.
Its share of the terminal antacid market in Chinese urban physical pharmacies exceeds 52%
.
In the second batch of centralized procurement, Shunfeng Pharmaceutical and Watson Pharmaceutical won the bid for this product
.
It was introduced at the meeting that the effect of price cuts will continue to be released in 2021
.
Compared with the year after the implementation of the centralized procurement results, the average price of medicines in 2021 will drop by 25.
7%, and the average price of selected medicines will drop by 29.
1%
.
In addition, the selected generic drugs continue to replace the unselected original research drugs and the effect of unselected generic drugs continues to increase
.
Compared with one year after the implementation of the centralized procurement results, the market share of selected generic drugs in 2021 has increased to 84.
4%, while the market share of original research drugs has fallen to 11.
7%
.
At present, the seventh round of centralized procurement is ready to come out.
The industry predicts that under the normalization of centralized procurement, not only generic drugs, but also original research drugs, including unselected products, have also become a trend, which will be a boon for patients
.
The centralized procurement has attracted the participation of a large number of pharmaceutical companies through the principle of "price-for-quantity"
.
Data show that the purchase volume of selected drugs increased by 265%, which in turn drove the price reduction of unselected drugs, including unselected original research drugs, and some products even fell by 34%, bringing benefits to patients
.
At the press conference on changes in the use of unselected original research drugs held on December 15th, 9 original drugs including atorvastatin oral regular-release dosage form and amlodipine oral regular-release dosage form were introduced, and the results of the collection were compared before and after implementation.
In terms of prices and procurement volume in one year, the procurement volume of unselected original research drugs has been significantly reduced.
The year after the implementation of centralized procurement results has dropped by an average of 46% compared with the year before implementation
.
In terms of prices, the average drop of the unselected original research drugs of the 9 drugs reached 12.
9%
.
Among them, the price of the original research drug of the heavy blood pressure lowering drug-valsartan oral regular-release dosage form has dropped by 20.
8%
.
This product is the third batch of collected varieties.
Five local companies including Changzhou Siyao, China Resources SECCO, Huahai Pharmaceutical, Hunan Qianjin Xiangjiang and Tianda Pharmaceutical won the bid.
The original research manufacturer Novartis was not selected
.
According to data from Meinenet, in 2020, the total sales of valsartan in Chinese public medical institutions and physical pharmacies in cities in China will exceed 5 billion yuan
.
Followed by the oral regular-release dosage form of atorvastatin, which decreased by 20.
7%
.
In the centralized procurement and expansion carried out in 2019, the winning bidders of the lipid-lowering drug atorvastatin calcium were Qilu Pharmaceutical, Xin'an Pharmaceutical, and Lepu, while the original research Pfizer did not win the bid
.
According to data from Menet.
com, the size of the terminal chemical drug market in physical pharmacies in key cities in 2020 will exceed 50 billion yuan, of which atorvastatin calcium tablets top the list with 1.
06 billion yuan
.
It was once again an oral regular-release dosage form of rosuvastatin, with a decrease of 19.
0%
.
This product is a selective HMG-CoA reductase inhibitor, suitable for the treatment of primary hypercholesterolemia or mixed dyslipidemia that cannot be properly controlled after diet control and other non-drug treatments (such as exercise therapy, weight loss) Dyslipidemia
.
The original research manufacturer of rosuvastatin was AstraZeneca.
It is understood that in the "4+7" centralized procurement pilot, the winning bidder was Jingxin Pharmaceutical, while in the expansion of centralized procurement, the winning bidder of rosuvastatin included overseas companies.
Zhengyao, Sandoz, Zhengda Tianqing
.
According to data from Menet.
com, the total sales of rosuvastatin calcium tablets in China's public medical institutions and retail pharmacies in cities in China in 2017 were 5.
839 billion yuan, of which the sales in China's public medical institutions were 5.
019 billion yuan, a year-on-year increase The annual growth rate was 22.
86%
.
In addition, hydromagnesium carbonate chewable tablets, the decline has reached 6.
5%
.
Chewable hydrotalcite is a commonly used gastro-protective medicine, which protects the gastrointestinal tract by directly neutralizing gastric acid.
Its share of the terminal antacid market in Chinese urban physical pharmacies exceeds 52%
.
In the second batch of centralized procurement, Shunfeng Pharmaceutical and Watson Pharmaceutical won the bid for this product
.
It was introduced at the meeting that the effect of price cuts will continue to be released in 2021
.
Compared with the year after the implementation of the centralized procurement results, the average price of medicines in 2021 will drop by 25.
7%, and the average price of selected medicines will drop by 29.
1%
.
In addition, the selected generic drugs continue to replace the unselected original research drugs and the effect of unselected generic drugs continues to increase
.
Compared with one year after the implementation of the centralized procurement results, the market share of selected generic drugs in 2021 has increased to 84.
4%, while the market share of original research drugs has fallen to 11.
7%
.
At present, the seventh round of centralized procurement is ready to come out.
The industry predicts that under the normalization of centralized procurement, not only generic drugs, but also original research drugs, including unselected products, have also become a trend, which will be a boon for patients
.
